Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett Buys 12,500 Shares of Stock

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett purchased 12,500 shares of the stock in a transaction on Friday, September 25th. The shares were purchased at an average cost of $20.23 per share, with a total value of $252,875.00. Following the transaction, the chief executive officer owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ:DMRA opened at $20.75 on Tuesday. The firm has a market capitalization of $1.28 billion, a PE ratio of -6.16 and a beta of 1.46. The business has a 50-day moving average of $28.18 and a two-hundred day moving average of $26.27. Damora Therapeutics, Inc. Common Stock has a 12 month low of $3.50 and a 12 month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. As a group, research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth about $42,146,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter worth $7,398,000. Squarepoint Ops LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $303,000. Finally, Arizona State Retirement System bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DMRA. Guggenheim boosted their price target on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Wedbush upped their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has a consensus rating of “Buy” and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.